Personalized medicine

Bionest is a Powerhouse in PM Strategy Thought Leadership. Team members developed articles covering broad aspects in PM.

Selected Publications :

 Business, Commercial and Regulatory :

• "How to Optimize Personalized Medicine R&D and Commercialization Decision-Making" (published in a supplement to Science, Dec. 23, 2011, and in collaboration with the Personalized Medicine Coalition).
• "Quantifying Stratified Medicine Success Factors: A Multi-stakeholder Perspective" (Published by Nature Review Drug Discovery, Nov. 2011, and co-authored by the cross-industry FDA Personalized Medicine Initiative consortium team. The article investigates and quantifies the various factors impacting financial value of stratified medicine and companion diagnostic tests to enable optimal R&D/commercialization decision-making).
• "Everywhere or Barely Anywhere? Defining and Quantifying Trends in the Practice of Personalized Medicine" (In collaboration with the MIT Sloan School of Management, IMS Health and the Harvard Medical School/Harvard School of Public Health. The article attempts to define, standardize and quantify this emerging and growing field of personalized medicine. Submitted to a major journal).
• "Pharmacogenomics and Personalized Medicine: Mapping of Future Value Creation" (It describes a top line view on how value would be created or re-allocated among the many healthcare industries including pharma, diagnostics etc. in the future world of personalized medicine. Published in BioTechniques).
• "The Biomarker as a companion diagnostic tool of therapeutic products—Impacts on R&D and the business models of Healthcare industrials" (A report for and published online by LEEM—the French Pharmaceutical Companies Association).

 Clinical and Scientific :

• "The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine" (published by the peer-reviewed journal Current Drug Metabolism, April 2011, and in collaboration with the Harvard Medical School, it provides a comprehensive snap shot of the impact of single nucleotide polymorphisms (SNPs) — a specific type of genetic biomarkers — as personalized medicine diagnostic tests by reviewing their scientific, clinical and regulatory aspects).
• "BeadArray™-based Solutions for Enabling the Promise of Pharmacogenomics" (Discussing some DNA-chip based technology to enable personalized medicine/biomarker R&D. Published in BioTechniques).
• "Noninvasive Prediction of Tumor Responses to Gemcitabine Using Positron Emission Tomography" (Exploration of the use of new, imaging-based biomarker to predict cancer patient response to gemcitabine. Published in Proceedings of the National Academy of Sciences).